Difference between revisions of "Denintuzumab mafodotin (SGN-CD19A)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Halted" to "Category:Halted drugs") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapy" to "Category:Chemotherapeutic") |
||
Line 6: | Line 6: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
− | [[Category: | + | [[Category:Chemotherapeutic]] |
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
Revision as of 18:11, 3 February 2019
Mechanism of action
Antibody-drug conjugate
Preliminary studies
- Abstract: Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) link to original abstract